<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01225640</url>
  </required_header>
  <id_info>
    <org_study_id>B1171003</org_study_id>
    <nct_id>NCT01225640</nct_id>
  </id_info>
  <brief_title>PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay</brief_title>
  <official_title>A Phase 2a, Open-Label, Randomized Study In Treatment-Naive, Sputum Smear Positive Subjects With Drug-Sensitive Pulmonary Tuberculosis To Assess Early Bactericidal Activity (EBA) And Whole Blood Activity (WBA) Of PNU-100480 (PF-02341272)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sequella, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sequella, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PNU-100480 is being developed for the treatment of both drug resistant and sensitive&#xD;
      tuberculosis. This is an efficacy and safety study to characterize the effect of PNU-100480&#xD;
      when given for 14 days to treatment-naive patients with drug-sensitive pulmonary&#xD;
      tuberculosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is rate of change in sputum log CFU/mL count (EBA) from Days 0-2.</measure>
    <time_frame>Days 0-2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of change in sputum log CFU/mL count (extended EBA).</measure>
    <time_frame>Days 2-14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in sputum log CFU/mL count (extended EBA).</measure>
    <time_frame>Days 0-14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in culture time to positivity (TTP) measured by MGIT and in log transformed TTP</measure>
    <time_frame>Days 02-; 2-14; 0-14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative whole blood bactericidal activity (measured as log reduction in CFU) against intracellular M. tuberculosis relative to administered dose and drug PK</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative whole blood bactericidal activity (measured as log reduction in CFU) against intracellular M. tuberculosis relative to administered dose and drug PK</measure>
    <time_frame>Day 13-14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of PNU-100480 and PNU-101603 will be used to determine PK parameters (AUCtau, AUC tau,ss, Cmax, Tmax, terminal half-life t1/2, Cavg, Rac) as data permit</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of PNU-100480 and PNU-101603 will be used to determine PK parameters (AUCtau, AUC tau,ss, Cmax, Tmax, terminal half-life t1/2, Cavg, Rac) as data permit</measure>
    <time_frame>Day 13-14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments including physical exams, AEs, laboratory tests, ECGs, and vital signs.</measure>
    <time_frame>Phys exam, AEs, and vitals are done at every visit (Screening through Day 15, Day 42/Follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments including physical exams, AEs, laboratory tests, ECGs, and vital signs.</measure>
    <time_frame>ECGs are done at Screening, Day 1, Day 14, 15 and 42/Follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments including physical exams, AEs, laboratory tests, ECGs, and vital signs.</measure>
    <time_frame>Lab tests at Screening, Day 1, Day 15 and 42/Follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>PNU-100480 600 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PNU-100480 1200 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RHZE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conjugated tablet with 4 drug combination of RHZE, RifafourÂ® e275 will be used in countries where can be sourced locally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PNU-100480</intervention_name>
    <description>600 mg twice daily (BID) for 14 days</description>
    <arm_group_label>PNU-100480 600 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PNU-100480</intervention_name>
    <description>1200 mg once daily (QD) for 14 days</description>
    <arm_group_label>PNU-100480 1200 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RHZE</intervention_name>
    <description>Combination tablet (RHZE) dosed by weight. Dosage strength per tablet is 150 mg Rifampicin (R)/75 mg Isoniazid (H)/400 mg Pyrazinamide (Z)/275 mg Ethambutol (E)</description>
    <arm_group_label>RHZE</arm_group_label>
    <other_name>Rifafour, Rimstar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult males or females between 18 and 65 years; women of childbearing potential must&#xD;
             be willing to adhere to lifestyle requirements regarding contraception/pregnancy&#xD;
             prevention.&#xD;
&#xD;
          -  Newly diagnosed sputum smear-positive pulmonary TB confirmed with acid-fast bacillus&#xD;
             (AFB) smear and chest x-ray. Patients with TB more than 5 years ago who completed&#xD;
             treatment, are healthy, and meet other inclusion criteria may be included.&#xD;
&#xD;
          -  Body weight between 40 and 90 kg, inclusive (in light clothing, no shoes).&#xD;
&#xD;
          -  Reasonably normal hemoglobin (&gt;=8 gm/dL), renal function (serum creatinine &lt;2 mg/dL),&#xD;
             hepatic function (serum AST &lt;3xULN and total bilirubin &lt;1.3 mg/dL), and random glucose&#xD;
             &lt;150 mg/dL.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV infection with helper/inducer T-lymphocytes (CD4 cell) count of &lt;=350x10-6/L.&#xD;
&#xD;
          -  Presence of significant hemoptysis. Subjects who cough up frank blood (more than blood&#xD;
             streaked sputum) will not be eligible.&#xD;
&#xD;
          -  Pregnant or nursing females; females of childbearing potential unwilling or unable to&#xD;
             adhere to contraception guidelines.&#xD;
&#xD;
          -  Significant respiratory impairment (respiratory rate &gt;35/minute).&#xD;
&#xD;
          -  Clinical suspicion of disseminated TB or tuberculosis meningitis.&#xD;
&#xD;
          -  Subjects with diabetes mellitus on insulin and/or who have poorly controlled disease.&#xD;
&#xD;
          -  Subjects with confirmed or suspected multi-drug resistant TB.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Beth Ferstenberg, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Sequella, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bellville</city>
        <state>Cape Town</state>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>October 19, 2010</study_first_submitted>
  <study_first_submitted_qc>October 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2010</study_first_posted>
  <disposition_first_submitted>March 19, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>March 19, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 25, 2013</disposition_first_posted>
  <last_update_submitted>December 14, 2015</last_update_submitted>
  <last_update_submitted_qc>December 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>EBA</keyword>
  <keyword>WBA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxazolidinones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

